Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
H
028300
vs
K
KOSPI 200
Over the past 12 months, HLB Inc has underperformed KOSPI 200, delivering a return of +28% compared to KOSPI 200's +116% growth.
Stocks Performance
028300 vs KOSPI 200
Performance Gap
028300 vs KOSPI 200
Performance By Year
028300 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
HLB Inc
Glance View
HLB Inc. is a South Korean biotech and healthcare company best known for developing cancer drugs and related medical products. Its core work is drug research, clinical development, and commercializing medicines through its own businesses and subsidiaries. It also has interests in medical devices and diagnostics, which gives it a broader role in the healthcare value chain than a pure drug developer. The company makes money in a few ways: selling medical and diagnostic products, licensing drug technology, and working with partners to advance drug candidates through development and approval. Its main customers are hospitals, clinics, doctors, and other healthcare companies, along with partners that help fund or distribute its products. In practice, HLB sits between the lab and the market, turning research programs into products that can be sold or partnered. What makes HLB different is that it is not just one drug business. It combines pharmaceutical development with healthcare devices and diagnostics, so it can build several revenue streams around the same medical ecosystem. That mix can help it keep working on long-term drug programs while also having more established product lines tied to everyday healthcare use.